



下載本文檔
版權(quán)說明:本文檔由用戶提供并上傳,收益歸屬內(nèi)容提供方,若內(nèi)容存在侵權(quán),請進(jìn)行舉報或認(rèn)領(lǐng)
文檔簡介
1、Hotline: 400-820-3792Inhibitors Agonists Screening Librarieswww.MedChemEVAS2870Cat. No.: HY-12804CAS No.: 722456-31-7分式: CHNOS分量: 360.39作靶點: NADPH Oxidase作通路: Metabolic Enzyme/Protease儲存式: Powder -20C 3 years4C 2 yearsIn solvent -80C 6 months-20C 1 month溶解性數(shù)據(jù)體外實驗 DMSO : 83.3 mg/mL (231.14 mM; Need u
2、ltrasonic)Mass Solvent1 mg 5 mg 10 mg Concentration制備儲備液1 mM 2.7748 mL 13.8739 mL 27.7477 mL5 mM 0.5550 mL 2.7748 mL 5.5495 mL10 mM 0.2775 mL 1.3874 mL 2.7748 mL請根據(jù)產(chǎn)品在不同溶劑中的溶解度,選擇合適的溶劑配制儲備液,并請注意儲備液的保存式和期限。體內(nèi)實驗 請根據(jù)您的實驗動物和給藥式選擇適當(dāng)?shù)娜芙獍福渲魄罢埾扰渲瞥吻宓膬湟?,再依次添加助溶?為保證實驗結(jié)果的可靠性,體內(nèi)實驗的作液,建議您現(xiàn)現(xiàn)配,當(dāng)天使;澄清的儲備液可以根據(jù)儲存條件
3、,適當(dāng)保存;以下溶劑前的百分 指該溶劑在您配制終溶液中的體積占):1. 請依序添加每種溶劑: 10% DMSO 40% PEG300 5% Tween-80 45% salineSolubility: 2.5 mg/mL (6.94 mM); Clear solution2. 請依序添加每種溶劑: 10% DMSO 90% corn oilSolubility: 2.5 mg/mL (6.94 mM); Clear solutionBIOLOGICAL ACTIVITY1/2 Master of Small Molecules 您邊的抑制劑師www.MedChemE物活性 VAS2870是NA
4、DPH氧化酶 (NADPH oxidase (NOX) 抑制劑。IC50 & Target Target: NADPH oxidase 1體外研究 VAS2870 is effective to suppress PDGF-BB-dependent activation of NADPH oxidase and subsequentproduction of intracellular ROS. Furthermore, VAS2870 suppresses PDGF-BB-dependent chemotaxis, butnot DNA synthesis. Preincubation wi
5、th VAS2870 (10 and 20 M) completely abolishes PDGF-mediatedNADPH oxidase activation and ROS production. Preincubation with VAS2870 (0.1-20 M) does not affectPDGF-induced cell cycle progression. However, it abolishes PDGF-dependent chemotaxis of VSMC in aconcentration-dependent manner (100% inhibitio
6、n at 10 M) 1. VAS2870 inhibits dose-dependentlyautocrine increase of cell number in FaO rat hepatoma cells, and almost completely blocked ROS productionand thymidine incorporation when used at 25 mM. VAS2870 blocks serum-dependent cell growth of FaO rathepatoma cells. VAS2870 inhibits proliferation
7、of different human hepatocellular carcinoma (HCC) cell lines.VAS2870 pretreatment enhances TGF-b-mediated apoptosis of FaO rat hepatoma cells 2.PROTOCOLKinase Assay 1 NADPH oxidase activity is measured by lucigenin-enhanced chemiluminescence in a 50 mM phosphatebuffer (buffer A), pH 7.0, containing
8、1 mM EGTA, protease inhibitors, 150 mM sucrose, 5 M lucigenin, and250 M NADPH as substrate. Quiescent cells are starved by serum deprivation for 24 h and treated asindicated, ished twice with ice-cold phosphate buffered saline (PBS), pH 7.4, and harvested. After low spincentrifugation, the pellet is
9、 re-suspended in ice-cold buffer A, lacking lucigenin and substrate. Then, the cellsare lysed and total protein concentration is determined using a Bradford assay and adjusted to 1 mg/mL. 100L aliquots of the protein sample are measured over 6 min in quadruplicates using NADPH (100 M) assubstrate in
10、 a scintillation counter. Data are collected at 2 min intervals in order to measure relative changesin NADPH oxidase activity 1.MCE has not independently confirmed the accuracy of these methods. They are for reference only.Cell Assay 2 To test autocrine growth, cells are serum deprived at 40% conflu
11、ence and, when indicated, the NADPHoxidase inhibitors Apocynin (300 mM) or VAS2870 are added 30 min before serum deprivation andmaintained along the experiment. For TGF-b experiments, cells at 70% confluence are serum deprived for 16h and treated with 2 ng/mL TGF- in the presence or absence of the E
12、GFR inhibitor AG1478 (20 mM) orVAS2870 (25 mM), which are added 30 min prior to TGF- 2.MCE has not independently confirmed the accuracy of these methods. They are for reference only.REFERENCES1. ten Freyhaus H, et al. Novel Nox inhibitor VAS2870 attenuates PDGF-dependent smooth muscle cell chemotaxis, but not proliferation.Cardiovasc Res. 2006 Jul 15;71(2):331-41.2. Sancho P, et al. The NADPH oxidase inhibitor VAS2870 impairs cell growth and enhances TGF-induced apoptosis of liver tumor cells.Biochem Pharmacol. 2011 Apr 1;81(7):917-24.McePdfHeight2/2 Master of Small Molecules 您邊的抑制劑師www.Med
溫馨提示
- 1. 本站所有資源如無特殊說明,都需要本地電腦安裝OFFICE2007和PDF閱讀器。圖紙軟件為CAD,CAXA,PROE,UG,SolidWorks等.壓縮文件請下載最新的WinRAR軟件解壓。
- 2. 本站的文檔不包含任何第三方提供的附件圖紙等,如果需要附件,請聯(lián)系上傳者。文件的所有權(quán)益歸上傳用戶所有。
- 3. 本站RAR壓縮包中若帶圖紙,網(wǎng)頁內(nèi)容里面會有圖紙預(yù)覽,若沒有圖紙預(yù)覽就沒有圖紙。
- 4. 未經(jīng)權(quán)益所有人同意不得將文件中的內(nèi)容挪作商業(yè)或盈利用途。
- 5. 人人文庫網(wǎng)僅提供信息存儲空間,僅對用戶上傳內(nèi)容的表現(xiàn)方式做保護(hù)處理,對用戶上傳分享的文檔內(nèi)容本身不做任何修改或編輯,并不能對任何下載內(nèi)容負(fù)責(zé)。
- 6. 下載文件中如有侵權(quán)或不適當(dāng)內(nèi)容,請與我們聯(lián)系,我們立即糾正。
- 7. 本站不保證下載資源的準(zhǔn)確性、安全性和完整性, 同時也不承擔(dān)用戶因使用這些下載資源對自己和他人造成任何形式的傷害或損失。
最新文檔
- 學(xué)徒烘焙合同范本
- 2025年銀色金屬弦項目可行性研究報告
- 2025年鍍鋅板板材項目可行性研究報告
- 2025至2030年中國大型不銹鋼設(shè)備數(shù)據(jù)監(jiān)測研究報告
- 2025年車架后叉項目可行性研究報告
- 2025年茶籽油項目可行性研究報告
- 成都四川成都簡陽市三合鎮(zhèn)便民服務(wù)和智慧蓉城運行中心招聘綜治巡防隊員2人筆試歷年參考題庫附帶答案詳解
- 2025至2030年中國霍爾效應(yīng)傳感IC數(shù)據(jù)監(jiān)測研究報告
- 2025至2030年中國防偽收縮膜數(shù)據(jù)監(jiān)測研究報告
- 塑料封皮合同范本
- 2025年春新外研版(三起)英語三年級下冊課件 Unit3第1課時startup
- FSC培訓(xùn)課件教學(xué)課件
- 2025年福建福州地鐵集團(tuán)招聘筆試參考題庫含答案解析
- 康復(fù)健康小屋課件
- 《內(nèi)部審計程序》課件
- 江西省宜春市豐城市第九中學(xué)2024-2025學(xué)年九年級上學(xué)期第二次段考化學(xué)試卷(日新班)(無答案)
- 江蘇省2024-2025年跨地區(qū)職業(yè)學(xué)校職教高考一輪聯(lián)考(機(jī)械專業(yè)綜合理論試卷含答案)
- 2024年事業(yè)單位租車服務(wù)滿意度調(diào)查及改進(jìn)協(xié)議3篇
- 露天礦邊坡穩(wěn)定課件所有章節(jié)整合
- 運用PDCA提高吞咽障礙患者護(hù)理措施落實率
- 《法學(xué)概論》課程教學(xué)大綱
評論
0/150
提交評論